Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
Yoshimura S, Panetta JC, Hu J, Li L, Gocho Y, Du G, Umezawa A, Karol SE, Pui CH, Mullighan CG, Konopleva M, Stock W, Teachey DT, Jain N, Yang JJ. Yoshimura S, et al. Among authors: stock w. Leukemia. 2023 Jun;37(6):1194-1203. doi: 10.1038/s41375-023-01900-5. Epub 2023 Apr 19. Leukemia. 2023. PMID: 37076694 Free PMC article.
Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.
Rowland L, Smart B, Brown A, Dettorre GM, Gocho Y, Hunt J, Yang W, Yoshimura S, Reyes N, Du G, John A, Maxwell D, Stock W, Kornblau S, Relling MV, Inaba H, Pui CH, Bourquin JP, Karol SE, Mullighan CG, Evans WE, Yang JJ, Crews KR. Rowland L, et al. Among authors: stock w. Bio Protoc. 2023 Aug 5;13(15):e4731. doi: 10.21769/BioProtoc.4731. eCollection 2023 Aug 5. Bio Protoc. 2023. PMID: 37575398 Free PMC article.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. Zhao Y, et al. Among authors: stock w. Blood Adv. 2024 Jun 25;8(12):3226-3236. doi: 10.1182/bloodadvances.2023012430. Blood Adv. 2024. PMID: 38607410 Free PMC article. Clinical Trial.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Luskin MR, Murakami MA, Keating JH, Flamand Y, Winer ES, Garcia JS, Stahl M, Stone RM, Wadleigh M, Jaeckle SL, Hagopian E, Weinstock DM, Liegel J, McMasters M, Wang ES, Stock W, DeAngelo DJ. Luskin MR, et al. Among authors: stock w. Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800. Online ahead of print. Blood. 2024. PMID: 39374521
Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces.
Gallardo-Pérez MM, Gale RP, Reyes-Cisneros OA, Sánchez-Bonilla D, Fernández-Gutiérrez JA, Stock W, Murrieta-Álvarez I, Olivares-Gazca JC, Ruiz-Delgado GJ, Fonseca R, Ruiz-Argüelles GJ. Gallardo-Pérez MM, et al. Among authors: stock w. Front Oncol. 2023 Jun 16;13:1187268. doi: 10.3389/fonc.2023.1187268. eCollection 2023. Front Oncol. 2023. PMID: 37397374 Free PMC article.
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
Fan H, Xia S, Xiang J, Li Y, Ross MO, Lim SA, Yang F, Tu J, Xie L, Dougherty U, Zhang FQ, Zheng Z, Zhang R, Wu R, Dong L, Su R, Chen X, Althaus T, Riedell PA, Jonker PB, Muir A, Lesinski GB, Rafiq S, Dhodapkar MV, Stock W, Odenike O, Patel AA, Opferman J, Tsuji T, Matsuzaki J, Shah H, Faubert B, Elf SE, Layden B, Bissonnette BM, He YY, Kline J, Mao H, Odunsi K, Gao X, Chi H, He C, Chen J. Fan H, et al. Among authors: stock w. Nature. 2023 Nov;623(7989):1034-1043. doi: 10.1038/s41586-023-06749-3. Epub 2023 Nov 22. Nature. 2023. PMID: 37993715 Free PMC article.
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.
Palmer A, Rauscher G, Abraham I, Burkart M, Dave A, Raptis N, Aleem A, Gannamani V, Erra A, Monick S, Galvez C, Shah S, Rahmani Youshanlouei H, Larson ML, Zia M, Tsai SB, Altman JK, Stock W, Khan I, Patel AA. Palmer A, et al. Among authors: stock w. Blood Adv. 2024 Sep 10;8(17):4647-4650. doi: 10.1182/bloodadvances.2024013280. Blood Adv. 2024. PMID: 38810264 Free PMC article. No abstract available.
Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Aldoss I, et al. Among authors: stock w. Blood Adv. 2024 Aug 2:bloodadvances.2024013747. doi: 10.1182/bloodadvances.2024013747. Online ahead of print. Blood Adv. 2024. PMID: 39093952
608 results